Johnson & Johnson — Janssen Pharmaceuticals
Tracked across 7 events · 47 articles · First seen May 19, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Johnson & Johnson — Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, is responsible for the further development and commercialization of ICOTYDE.
May 28, 2026 · 6 articles
Business
Impact: Subject of pending litigation with XOMA Royalty regarding TREMFYA; CVRs tied to potential proceeds.
Jul 14, 2026 · 6 articles
Business
Impact: Johnson & Johnson — Janssen Pharmaceuticals, a Johnson & Johnson company, is licensed to commercialize ICOTYDE, a peptide therapeutic jointly discovered with AnBogen Therapeutics.
Jun 16, 2026 · 6 articles
Business
Impact: Assertio Therapeutics>>> acquired Nucynta from Johnson & Johnson — Janssen Pharmaceuticals>>>.
May 19, 2026 · 6 articles
Business
Impact: Johnson & Johnson — Janssen Pharmaceuticals is mentioned as a collaborator with Nanobiotix on certain clinical trials, indicating ongoing partnerships, though not directly related to the trading halt.
May 21, 2026 · 7 articles
Business
On September 8, 2026, AnBogen Therapeutics announced that its Board of Directors authorized a share repurchase program of up to $300 million of its outstanding common stock. The company plans to fund the repurchases using…
Impact: Johnson & Johnson — Janssen Pharmaceuticals, a Johnson & Johnson company, is the licensee of ICOTYDE. Its commercialization efforts generate royalties that support Protagonist's cash flow, indirectly enabling the repurchase.
Sep 08, 2026 · 7 articles
Business
Impact: Johnson & Johnson — Janssen Pharmaceuticals, a J&J subsidiary, is the licensee of ICOTYDE. No direct impact from this event.
Aug 04, 2026 · 9 articles
ERGEN INTELLIGENCE
Track Johnson & Johnson — Janssen Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard